The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.
From State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.
How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.
How actively engaging millennials can help manage healthcare staffing challenges.
Oncology Institute’s Dawn Holcombe, MBA, FACMPE, ACHE, shares her views on the OCM program, what CAR T-cell therapy means for the future of reimbursement, and some epic predictions.
How did Trump’s actions in 2017 impact the health insurance marketplace and enrollment numbers? Find out.
With influenza activity increasing sharply, here’s how healthcare executives can determine which health plan members are at risk for the flu.
More reports of sexual harassment in the workplace are arising every day. It’s time to rethink your prevention strategies.
Trump’s new proposal would broaden access to association health plans. Here’s six things to know.
Managed Healthcare Executive board members identify top challenges. How does your list compare?